February 7, 2008
Botox competitors can't come soon enough
Analysis of:
Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: Botox from Allergan has enjoyed an exclusive monopoly for the past nine years. Alternative drugs do not appear to be available as soon as was hoped.
Analysis: Botox (Botulinum toxin A) has been a boon to Allergan and to cosmetic surgery. Over 4,000,000 Botox injections were given in 2006 which account for over a third of Allergans profits. Not surprisingly competitor products have been in the works from both Medicis (Reloxin) and Mentor (Puretox). Unfortunately, for patients and clinicians neither of these competitors can come soon enough.
Analysis: Botox (Botulinum toxin A) has been a boon to Allergan and to cosmetic surgery. Over 4,000,000 Botox injections were given in 2006 which account for over a third of Allergans profits. Not surprisingly competitor products have been in the works from both Medicis (Reloxin) and Mentor (Puretox). Unfortunately, for patients and clinicians neither of these competitors can come soon enough.
Reloxin which was to be available this quarter has been delayed by FDA and will likely not be available until 2nd or 3rd quarter of this year. Puretox is not scheduled to be available until 2010.
In the meantime, Allergan now charges over $500 per 100 unit vial of Botox, an increase of over 50% from its cost nine years ago. Practitioners have had difficulty passing these costs along to patients as Botox has become available from more physicians looking to augment their sagging insurance reimbursements and from medi-spas.
Hopefully, competitors will offer not only less expensive alternatives.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
www.medicalnewstoday.com
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
www.therapeuticsdaily.com
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
jco.ascopubs.org
ACE Inhibitor May Ease Cardiac Risks in Marfan's Syndrome
www.medpagetoday.com
Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment
online.wsj.com
Azilect
September 2, 2008
Byetta Saves Lives
September 2, 2008
The Devil Is in the Details
September 1, 2008
Dangers of Methadone Usage
August 28, 2008
Healthways A Market Downturn and Results
August 26, 2008